Antiverse, a biotech company developing a computational antibody drug discovery platform, is extending its collaboration with GlobalBio, an antibody engineering company, to advance immune checkpoint inhibitors in cancer therapy.
Ultimovacs, a clinical-stage biotech developing novel immunotherapeutic cancer vaccines, has announced ‘encouraging’ overall survival (OS) data for its phase 1 clinical trial in malignant melanoma.
Synaffix, a Lonza company commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has entered a licensing agreement with SOTIO, a clinical stage immuno-oncology company owned by PPF Group.
The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.
Terumo Blood and Cell Technologies, a medical tech company, and BioCentriq, a cell therapy contract development and manufacturing organization (CDMO), are working together to demonstrate the capabilities of Terumo’s automated cell and gene therapy platforms...
Children’s Mercy Kansas City, an independent pediatric health organization, has become the first health care system to replace old genetic tests, such as rapid exome and chromosomal microarray analysis, with the world’s most-advanced genomic sequencing...
OrganaBio, a contract technology development and manufacturing organization (CTDMO) specializing in solutions for cell and immunotherapy development, has launched a new division.
ScaleReady, a cell therapy manufacturing company, and CTMC, a joint venture between National Resilience and the MD Anderson Cancer Center, have entered into a new collaborative partnership
Congenica, a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale, has announced a two-year extension to its contract for the Hong Kong Genome Project (HKGP), the first large-scale genome...
Sharp, a commercial pharma packaging and clinical trial supply services firm, has acquired Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO).
CellProthera is moving forward with its cell therapy which regenerates damaged tissue following a severe heart attack, restoring cardiac function and effectively mending a broken heart.
BPGbio, an AI-powered biopharma that focuses on oncology, neurology, and rare diseases, is advancing its pancreatic cancer drug BPM 31510 IV after a positive phase 1 and 2a study.
Evozyne has announced the closing of an $81 million series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development.
Laverock Therapeutics, the gene editing-induced gene silencing platform for human therapeutic applications, has expanded its seed funding round to £13.5 million.
Mount Sinai investigators have developed a new approach for treating invasive bladder cancer without the need for surgical removal of the bladder, according to a study published in Nature Medicine in September.
Across the global life sciences supply chain, data, digitalization, automation, and artificial intelligence are driving the most innovation, according to a new survey from CRB.
At Advanced Therapies Europe 2023, BioPharma Reporter caught up with ScaleReady's Jenny Stjernberg to discuss her work at the biotech company, her journey from academia to commercial and female representation in the cell and gene therapies industry....
Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis...
Eli Lilly has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab for the treatment of adults with moderately to severely active Ulcerative Colitis (UC).
A new treatment for esophageal squamous cell carcinoma (ESCC) from Shanghai-based Henlius Biotech has been approved by the National Medical Products Administration (NMPA).
A rescue medication could help reverse the effect of the most powerful synthetic opioids including fentanyl if accepted by the US Food and Drug Administration (FDA).
The UK startup Broken String Biosciences has raised a $15 million Series A round to fund the development of a DNA sequencing platform that maps off-target DNA breaks resulting from genome editing technology.
The contract development and manufacturing organization (CDMO) Fujifilm Diosynth Biotechnologies has completed a UK manufacturing facility for the production of advanced therapies including viral gene therapies, oncolytic viruses and viral vaccines for...
LabGenius, a company focused on machine learning (ML) for antibody discovery, has presented key data in a poster presentation at the Single-Domain Antibodies 2023 Meeting.
Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.
Vaxess Technologies, a life sciences company developing a shelf-stable vaccine patch with potential for self-application, has announced an additional $9 million in venture capital funding, with investors including RA Capital, The Engine, and GHIC, and...
Arrowhead Pharmaceuticals has spotlighted the potential of RNA interference (RNAi) therapeutic candidates in the lungs, with a clinical late breaker and multiple pre-clinical presentations at this year’s European Respiratory Society (ERS) International...
Kuano, a drug discovery company combining quantum mechanics with AI, has announced the close of its £1.8 million seed funding round, led by Mercia Ventures, and including ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP, and other...
TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, has been awarded a £995,000 grant from Innovate UK.
Chiesi, the biopharmaceutical and healthcare group, has announced that the National Institute for Health and Care Excellence (NICE) has recommended Elfabrio (pegunigalsidase alfa) as a treatment for Fabry disease in adults.
BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history,...
Octave Bioscience, a precision care company advancing treatments for multiple sclerosis (MS), has announced the publication of the successful clinical validation of its multiple sclerosis disease activity (MSDA) test in the peer-reviewed journal Clinical...
Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.
Cancer immunotherapy, more commonly known as immuno-oncology, continues to gather momentum. As a rapidly evolving field, ongoing research and advancements are coming together to expand the number of available treatments, many of which are showing incredible...
Quest Diagnostics, a provider of diagnostic information services, has announced that its AAVrh74 ELISA assay (CDx) has been granted breakthrough device designation from the U.S. Food and Drug Administration (FDA).
Optibrium, a developer of software and AI solutions for drug discovery, has acquired BioPharmics in a view to expand its 3D drug design and modelling offering.
GEDiCube is joining NVIDIA Inception, a program which guides start-ups by providing access to cutting-edge technology, technical resources, and venture capitalists.
